The Medicines Company(NasdaqGS:MDCO) dropped from S&P 1000

The Medicines Company is a global biopharmaceutical company. The Company is focused on the development of inclisiran, a twice-yearly therapy that allows administration during patients routine visits to their healthcare professionals and potentially contributes to improved patient adherence and sustained lower LDL-C levels. The Company is a subsidiary of Novartis AG.